Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hobeika

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Oncogene|May 16, 1998
Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell lineP S Subramaniam, P E Cruz, A C Hobeika, et al.
Journal of Visceral Surgery|December 24, 2019
Metabolic syndrome and hepatic surgeryC Hobeika, M Ronot, A Beaufrere, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1995
The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicityJ M Soos, P S Subramaniam, A C Hobeika, et al.
Experimental Biology and Medicine (Maywood, N.J.)|May 22, 2001
Superantigens: the good, the bad, and the uglyB A Torres, S Kominsky, G Q Perrin, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 1995
Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-V beta 8-specific superantigenJ M Soos, A C Hobeika, E J Butfiloski, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 19, 2000
IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosisA C Hobeika, W Etienne, B A Torres, et al.
International Journal of Cancer|June 25, 1998
IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potentialA C Hobeika, W Etienne, P E Cruz, et al.
Critical Reviews in Immunology|October 20, 2001
Quantitating therapeutically relevant T-cell responses to cancer vaccinesA C Hobeika, T M Clay, P J Mosca, et al.
Expert Opinion on Biological Therapy|December 1, 2001
Surrogate markers of response to cancer immunotherapyM A Morse, T M Clay, A C Hobeika, et al.
Surgery|March 7, 2001
Direct detection of cellular immune responses to cancer vaccinesP J Mosca, A C Hobeika, T M Clay, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Oncogene|May 16, 1998
Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell lineP S Subramaniam, P E Cruz, A C Hobeika, et al.
Journal of Visceral Surgery|December 24, 2019
Metabolic syndrome and hepatic surgeryC Hobeika, M Ronot, A Beaufrere, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1995
The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicityJ M Soos, P S Subramaniam, A C Hobeika, et al.
Experimental Biology and Medicine (Maywood, N.J.)|May 22, 2001
Superantigens: the good, the bad, and the uglyB A Torres, S Kominsky, G Q Perrin, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 1995
Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-V beta 8-specific superantigenJ M Soos, A C Hobeika, E J Butfiloski, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 19, 2000
IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosisA C Hobeika, W Etienne, B A Torres, et al.
International Journal of Cancer|June 25, 1998
IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potentialA C Hobeika, W Etienne, P E Cruz, et al.
Critical Reviews in Immunology|October 20, 2001
Quantitating therapeutically relevant T-cell responses to cancer vaccinesA C Hobeika, T M Clay, P J Mosca, et al.
Expert Opinion on Biological Therapy|December 1, 2001
Surrogate markers of response to cancer immunotherapyM A Morse, T M Clay, A C Hobeika, et al.
Surgery|March 7, 2001
Direct detection of cellular immune responses to cancer vaccinesP J Mosca, A C Hobeika, T M Clay, et al.
Pageof 6